IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer

Breast Cancer Clinical Trial

Official title:

A Phase I Prevention Trial of ACTIVIN Grape Seed Extract as an Aromatase Inhibitor In Healthy Postmenopausal Women at Risk for Breast Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00100893
• Other study ID #: 03178
• Secondary ID: P30CA033572CHNMC
• Status: Completed
• Phase: Phase 1
• First received: January 6, 2005
• Last updated: June 3, 2015
• Start date: January 2005
• Est. completion date: October 2013

Study information

• Verified date: June 2015
• Source: City of Hope Medical Center
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of IH636 grape seed extract may prevent breast cancer.

PURPOSE: This phase I trial is studying the side effects and best dose of IH636 grape seed extract in preventing breast cancer in postmenopausal women at risk of developing breast cancer.

Description:

OBJECTIVES:

• Determine the efficacy of IH636 grape seed proanthocyanidin extract, in terms of suppression of estrogen biosynthesis, in healthy post-menopausal women at high risk of developing breast cancer.

• Determine the safety and tolerability of this dietary supplement, in terms of symptoms and changes in markers of bone and lipid metabolism and in markers of nonspecific adrenal suppression, in these participants.

• Determine, preliminarily, an optimum biologic dose of this dietary supplement, as defined by suppression of serum estradiol, in these participants.

• Determine a minimum duration of use of this dietary supplement to achieve aromatase inhibition in these participants.

OUTLINE: This is a pilot, dose-finding, placebo-controlled study.

Participants receive oral placebo once or twice daily on days -14 to 0. Participants then receive oral IH636 grape seed proanthocyanidin extract once or twice daily on days 1-85. Treatment continues in the absence of toxicity.

Cohorts of 6 participants receive one of four dose levels of IH636 grape seed proanthocyanidin extract up to an established safe dose.

PROJECTED ACCRUAL: A total of 24 participants will be accrued for this study within 12 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 37
• Est. completion date: October 2013
• Est. primary completion date: October 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 40 Years to 75 Years

Eligibility

DISEASE CHARACTERISTICS:

• At risk of developing breast cancer

• No history of breast cancer or ductal carcinoma in situ

PATIENT CHARACTERISTICS:

Age

• 40 to 75

Sex

• Female

Menopausal status

• Postmenopausal, defined by 1 of the following criteria:

• No spontaneous menses for = 12 months

• Prior bilateral oophorectomy

• Prior hysterectomy with follicle-stimulating hormone within menopausal range

Performance status

• ECOG 0-1

Life expectancy

• Not specified

Hematopoietic

• Hemoglobin = 9.0 g/dL

• Platelet count = 100,000/mm^3

• WBC = 3,500/mm^3

• Absolute granulocyte count = 1,500/mm^3

• No coagulation disorders

Hepatic

• SGOT and SGPT = 2 times upper limit of normal (ULN)

• Bilirubin = 1.5 times ULN

Renal

• Creatinine = 1.5 times ULN

Cardiovascular

• No major illness of the cardiovascular system

Pulmonary

• No major illness of the respiratory system

Other

• No history of other invasive cancer within the past 5 years except squamous cell or basal cell skin cancer

• No major systemic infection

• No Cushing's syndrome or adrenal insufficiency

• No osteoporosis, defined as a bone mineral density T-score = -2.5 on dual-energy x-ray absorptiometry scan (calcium and/or cholecalciferol [vitamin D] supplementation AND/OR bisphosphonate therapy allowed provided participant is on a stable dose during study participation)

PRIOR CONCURRENT THERAPY:

Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• More than 3 months since prior hormone-modifying medications, including any of the following:

• Oral contraceptives

• Hormone replacement therapy

• Selective estrogen receptor modifiers

• Aromatase inhibitors

• Gonadotropin-releasing hormone modifiers

• Concurrent dehydroepiandrosterone (DHEA) allowed, provided dose remains constant during study participation

Radiotherapy

• Not specified

Surgery

• Not specified

Other

• No red wine, red grapes, or white button mushrooms directly before or during study treatment

• White and seedless grapes allowed

• No other concurrent therapy

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Dietary Supplement:
• IH636 grape seed proanthocyanidin extract
Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage

Locations

Country	Name	City	State
United States	City of Hope Comprehensive Cancer Center	Duarte	California

Sponsors (2)

Lead Sponsor	Collaborator
City of Hope Medical Center	National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Estrogen suppression as measured by serum estradiol, estrone, estrone sulfate, and sex hormone binding globulin		at 1, 2, 4, 8, and 12 weeks	No
Secondary	Androgenic effects as measured by serum testosterone, androstenedione, dehydroepiandrosterone (DHEA), and dehydroepiandrosterone sulfate (DHEAS)		at 1, 2, 4, 8, and 12 weeks	No
Secondary	Lipid effects as measured by total cholesterol, LDL, HDL, and triglycerides		at 12 weeks	No
Secondary	Bone metabolic effects as measured by bone-specific alkaline phosphatase and N-telopeptides		at 12 weeks	No
Secondary	Insulin regulatory effects as measured by insulin-like growth factor 1 (IGF1) and insulin-like growth factor-binding protein 3 (IGFBP3)		at 12 weeks	No
Secondary	Pharmacokinetics as measured by procyanidins		before and after first dose and then at 1, 2, 4, 8, and 12 weeks	No